Figure - uploaded by Bareq N. Al-Nuaimi
Content may be subject to copyright.
Source publication
Fluconazole was used to test the susceptibility of Candida albicans isolated from different clinical samples, and to detect mutations in ERG11 gene, and their relationship to fluconazole resistance. Forty-eight isolates of Candida albicans were tested for susceptibility using the disc diffusion method (M-44). ERG11 genes of six isolates were amplif...
Context in source publication
Context 1
... The amplified product in our study was extended from 332 to 1664 bp of the gene, since the hot spot regions of ERG11P located at 105-165, 266-287, and 405-488 [14]. The isolates (3,10) were isolated from different patients, but sharing the same mutations with nine silent (T462C, C558T, C805T, T1143C, A1173G, C1257T, T1350C, C1443T, and T1449G) including two missense mutations (A945C, and G1609A), and four silent mutations (A945C, G1609A, C1443T, and T1449C) detected only in these susceptible isolates (Table 5). These data can be an evidence that these two isolates are belonging to the same strain. ...Similar publications
- [...]
Purpose
RNA terminal phosphate cyclase like 1 (RCL1) undergoes overexpression during the immune response of Candida albicans following drug treatment. This study aims to investigate the expression levels of RCL1 in C. albicans under various stress conditions.
Methods
Fifteen itraconazole (ITR)-resistant strains of clinical C. albicans, and one sta...
Citations
... One of the biggest handicaps to achieving clinical success with azole is the resistance among species of Candida and Aspergillus. 8,9 Due to prolonged azole usage worldwide, Candida species resistant to azoles have increased, as the MICs level is rising and failure of clinical treatment. 10 Candida species examined worldwide, > 2.5% and > 9% of the yeast show resistance to both fluconazole and itraconazole. ...
Introduction: Candida spp. has become increasingly resistant to antifungal
drugs, with elevated MIC levels causing a negative medical impact and
increasing the number of patients at risk of candidiasis. According to the
CDC, about 7% of Candida blood samples show reduced susceptibility
to fluconazole. Monitoring the antifungal resistance profile of Candida
spp. is vital, as non-Albicans species may limit treatment options.
Objective: Evaluate the antifungal effectiveness against clinical Candida
spp. isolates of six antifungals: amphotericin B, fluconazole, voriconazole,
itraconazole, caspofungin, and 5-fluorocytosine.
Methods: 100 samples were collected from various clinical samples at
the National Centre of Teaching Laboratories in Baghdad, Iraq, from
May to December 2023. The effectiveness of six antifungals (fluconazole
(FLC), itraconazole (ITR), voriconazole (VRC), amphotericin B (AMB),
caspofungin (CAS), and 5-fluorocytosine (5-FC)) was tested using the
MA120 Automated ID and AST System (Render) according to CLSI
standards.
Results: Out of 100 isolates, nine Candida species were identified: C.
albicans (54%), C. glabrata (20%), C. dubliniensis (10%), C. tropicalis
(6%), C. krusei (5%), C. parapsilosis (2%), and C. rugosa, C. lusitaniae,
and C. kyfer (each 1%). The non-susceptible rates to the six antifungals
were: 5-FC (42%), FLC (21% intermediate, 9% resistant), AMB (11%),
ITR (8%), VRC (6%), CAS (4% intermediate, 1% resistant).
Conclusion: We observed increased resistance rates to 5-FC, FLC, ITR,
AMB, and VRC, but not to caspofungin. C. albicans showed a high 5-FC
non-WT phenotype (72%) with elevated MIC values, while C. glabrata
had a 7% non-WT rate against AMB. C. tropicalis and C. parapsilosis
revealed limited susceptibility to azoles.
